News and Announcements
Riccardo Canevari of Radiopharm Theranostics (ASX:RAD)
- Published December 06, 2022 6:49AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Radiopharm Theranostics (ASX:RAD) is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company has a pipeline of four distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer, from some of the world’s leading universities and institutes.
Watch this interview with CEO Riccardo Canevari as he discusses how they approach oncology with their unique processes.
Executive Interviews
7 Reasons Bitcoin Shines as the Apex of Technological Beauty
In the ever-evolving landscape of technology, Bitcoin stands as a beacon of innovation, not just in currency but in the philosophy of financial freedom and digital security. Here’s why Bitcoin is considered the zenith of technological beauty. 1. Decentralization Bitcoin’s decentralized nature is its philosophical cornerstone. It operates on a network where no single entity […]
Fun Facts about Bitcoin and Crypto
Crypto Investment Trends At Emergence 2024, I outlined how when it comes to innovation, first, innovators equal the incumbent, then they 10X beyond it. To celebrate this trend, here are 7 fun facts you may not know about the rise of Bitcoin and how it compares with incumbents, plus a fun fact about Coinbase: 1. […]
The Innovator Overtaking the Incumbent: A New Era in Mobility
The disruptor becomes the disrupted. The ride-sharing industry, once dominated by giants like Uber and Lyft, is witnessing a seismic shift. Waymo’s Ascendance With its relentless focus on autonomous driving technology, Waymo has steadily climbed the ranks. From a modest beginning, it’s now poised to challenge the market leaders. The graph beautifully illustrates this trajectory, […]
Backed By Leading Investment Groups and Family Offices
